Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
small interfering RNA targeting livin
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
Small interfering RNA targeting Livin is an experimental RNA interference (RNAi) therapeutic designed to treat various cancers, including malignant melanoma, colon cancer, and bladder cancer. Livin (also known as BIRC7) is a member of the inhibitor of apoptosis protein (IAP) family that is overexpressed in many tumors and contributes to treatment resistance. By specifically silencing Livin mRNA, this siRNA reduces Livin protein levels, thereby activating caspase-3 and inducing apoptosis while inhibiting tumor cell proliferation. Preclinical studies have explored its use as a monotherapy and in combination with chemotherapy (such as mitomycin-C) to enhance sensitivity. Delivery strategies, such as single-chain antibody-mediated systems, are being investigated to improve tumor-specific uptake and efficacy in xenograft models.
- Other names
- siRNA-LivinLivin siRNAsiRNA targeting Livin
02
Targets
BIRC7
Beyond the preview
Go deeper on small interfering RNA targeting livin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on small interfering RNA targeting livin.